Psoriasis Research Today is a free monthly online journal that collates and summarizes the latest research about Psoriasis, including details on treatment, prevention, medication, causes.

Volume 2 (2005), Issue 1 (January)

1. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model.
   Nat Med, 11(1): 43-9. [Abstract] [Full-text]
2. Sensorineural hearing loss associated with psoriatic arthritis.
   J Laryngol Otol, 118(11): 909-11. [Abstract] [Full-text]
3. p53 expression in rheumatoid and psoriatic arthritis synovial tissue and association with joint damage.
   Ann Rheum Dis, 64(2): 183-7. [Abstract] [Full-text]
4. Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab.
   Arthritis Rheum, 52(1): 280-2. [Abstract] [Full-text]
5. Dactylitis in psoriatic arthritis: a marker for disease severity?
   Ann Rheum Dis, 64(2): 188-90. [Abstract] [Full-text]
6. Protective effect of sensory denervation in inflammatory arthritis (evidence of regulatory neuroimmune pathways in the arthritic joint).
   Ann Rheum Dis, 64(2): 325-7. [Abstract] [Full-text]
7. Dimethylfumarate for psoriasis: more than a dietary curiosity.
   Trends Mol Med, 11(1): 43-8. [Abstract] [Full-text]
8. Prevalence of human papilloma virus type 5 DNA in lesional and non-lesional skin scales of Italian plaque-type psoriatic patients: association with disease severity.
   Clin Microbiol Infect, 11(1): 47-51. [Abstract] [Full-text]
9. Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme.
   J Eur Acad Dermatol Venereol, 19(1): 35-41. [Abstract] [Full-text]
10. Novel pharmacological approaches in the treatment of psoriasis.
    J Eur Acad Dermatol Venereol, 19(1): 1-20. [Abstract] [Full-text]
11. Psoriatic uveitis: a distinct clinical entity?
    Am J Ophthalmol, 139(1): 106-11. [Abstract] [Full-text]
12. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment.
    Arch Dermatol, 141(1): 43-6. [Abstract] [Full-text]
13. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Arch Dermatol, 141(1): 31-8. [Abstract] [Full-text]
14. Members of the national psoriasis foundation: more extensive disease and better informed about treatment options.
    Arch Dermatol, 141(1): 19-26. [Abstract] [Full-text]
15. Fos and jun proteins are specifically expressed during differentiation of human keratinocytes.
    J Invest Dermatol, 124(1): 212-20. [Abstract] [Full-text]
16. Characterization and differentiation-dependent regulation of secreted phospholipases A in human keratinocytes and in healthy and psoriatic human skin.
    J Invest Dermatol, 124(1): 204-11. [Abstract] [Full-text]
17. Lack of evidence for genetic association to RUNX1 binding site at PSORS2 in different German psoriasis cohorts.
    J Invest Dermatol, 124(1): 107-10. [Abstract] [Full-text]
18. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis.
    J Invest Dermatol, 124(1): 103-6. [Abstract] [Full-text]
19. Haplotype sharing analysis identifies a retroviral dUTPase as candidate susceptibility gene for psoriasis.
    J Invest Dermatol, 124(1): 99-102. [Abstract] [Full-text]
20. Proteome analysis of skin distinguishes acute guttate from chronic plaque psoriasis.
    J Invest Dermatol, 124(1): 63-9. [Abstract] [Full-text]
21. Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts.
    J Invest Dermatol, 124(1): 28-37. [Abstract] [Full-text]
22. Autoantibodies directed against the protease inhibitor calpastatin in psoriasis.
    Clin Exp Immunol, 139(2): 355-62. [Abstract] [Full-text]
23. Blood flow in psoriatic plaques before and after selective treatment of the superficial capillaries.
    Br J Dermatol, 152(1): 60-5. [Abstract] [Full-text]
24. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin.
    Br J Dermatol, 152(1): 37-42. [Abstract] [Full-text]
25. Primary annular plaque-type psoriasis.
    Pediatr Dermatol, 22(1): 15-8. [Abstract] [Full-text]
26. The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy.
    J Cutan Med Surg, 8: 20-5. [Abstract] [Full-text]
27. Alefacept is well tolerated in patients with chronic plaque psoriasis.
    J Cutan Med Surg, 8: 14-9. [Abstract] [Full-text]
28. The remittive effects of alefacept.
    J Cutan Med Surg, 8: 10-3. [Abstract] [Full-text]
29. The efficacy of alefacept in the treatment of chronic plaque psoriasis.
    J Cutan Med Surg, 8: 3-9. [Abstract] [Full-text]
30. Identification and characterization of novel variants of the thioredoxin reductase 3 new transcript 1 TXNRD3NT1.
    Mamm Genome, 16(1): 41-9. [Abstract] [Full-text]
31. Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis.
    J Invest Dermatol, 124(2): 373-83. [Abstract] [Full-text]
32. Immunohistochemical analysis of keratinocyte growth factor and fibroblast growth factor 10 expression in psoriasis.
    Exp Dermatol, 14(2): 130-7. [Abstract] [Full-text]

© 2004-2008 Psoriasis Research Today. All Rights Reserved.